Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02855359 · ClinicalTrials.gov registry record · Phase 2
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
A Phase 2 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02855359 is a Phase 2 study that was terminated before completion, run by Seagen. The registered enrollment target is 24 participants.
The verdict
NCT02855359, a Phase 2 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse large B-cell lymphoma or follicular lymphoma Grade 3b.
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG rituximab
- DRUG vincristine
- DRUG denintuzumab mafodotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02855359
The ClinicalTrials.gov registry entry for NCT02855359 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT02855359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02855359 about?
NCT02855359 is a clinical study titled "Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma". This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse large B-cell lymphoma or follicular lymphoma Grade 3b.
What is the current status of trial NCT02855359?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-08. Estimated completion is 2018-05-15.
What interventions are being tested in trial NCT02855359?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin (DRUG), rituximab (DRUG), vincristine (DRUG), denintuzumab mafodotin (DRUG).
Who is sponsoring clinical trial NCT02855359?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.